10.440.19% ( -0.02 )
Delay Closed: Nov 13, 15:00:00Valuation
Current ValuationThe current P/E ratio is -225.68, below the reasonable range, cheaper than 94.59% of the time in the past 1 years, and the industry ranks 81/84, the industry Median 19.64.
-225.68xP/E
¥10.44Stock price
¥-0.05Earnings per share
-225.68xP/E
Stock price¥10.44Earnings per share¥-0.05
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -106.19x
- Typical range
- -177.29x–-54.32x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 19.64x
017345168
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 19.64x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
300122SZZHIFEI-BIOL | -2.35x | 91.91% | ¥33.15B |
688180SHJunshi Biosciences | -71.37x | 81.90% | ¥30.60B |
603392SHWantai Biological | -63.41x | 22.02% | ¥28.89B |
300676SZBGI Genomics | -28.14x | 118.23% | ¥15.34B |
688520SHSinocelltech | -14.57x | 171.21% | ¥13.95B |
688765SHHEALTHGEN BIOTECH | -92.77x | -- | ¥13.14B |
688319SHOlymvax Biopharmaceuticals | -337.79x | 227.87% | ¥10.82B |
688806SHTrinomab Pharmaceutical | -22.46x | -- | ¥10.12B |
688137SHNovoprotein | -97.24x | -- | ¥9.42B |
688443SHGenrix Bio | -44.33x | 77.40% | ¥9.28B |
300204SZStaidson BioPharm | -92.61x | -- | ¥9.22B |
688062SHMabwell | -8.64x | 37.63% | ¥9.07B |
688382SHInventisBio | -20.14x | 5.45% | ¥7.64B |
688759SHBeBetter Med | -36.91x | 12.50% | ¥7.30B |
002030SZDAJY | -9.80x | -- | ¥7.28B |
688177SHBIO-THERA | -15.70x | 2.47% | ¥6.92B |
300294SZBOYA BIOLOGY | -39.97x | 306.82% | ¥6.71B |
688276SHBCHT | -31.96x | 66.67% | ¥6.39B |
002038SZSL PHARM | -6.16x | -- | ¥5.17B |
688221SHFroniter Biotechnologies | -137.77x | -- | ¥4.93B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
